Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy
- 4 July 2008
- journal article
- research article
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 22 (4), 897-904
- https://doi.org/10.1111/j.1939-1676.2008.0116.x
Abstract
Despite traditional therapy of a diuretic, angiotensin converting enzyme inhibitor, digoxin, or a combination of these drugs, survival of dogs with dilated cardiomyopathy (DCM) is low. Pimobendan, an inodilator, has both inotropic and balanced peripheral vasodilatory properties. Pimobendan when added to conventional therapy will improve morbidity and reduce case fatality rate in Doberman Pinschers with congestive heart failure (CHF) caused by DCM. Sixteen Doberman Pinschers in CHF caused by DCM. A prospective randomized, double-blind, placebo-controlled study with treatment failure as the primary and quality of life (QoL) indices as secondary outcome variables. Therapy consisted of furosemide (per os [PO] as required) and benazepril hydrochloride (0.5 mg/kg PO q12h) and dogs were randomized in pairs and by sex to receive pimobendan (0.25 mg/kg PO q12h) or placebo (1 tablet PO q12h). Pimobendan-treated dogs had a significant improvement in time to treatment failure (pimobendan median, 130.5 days; placebo median, 14 days; P= .002; risk ratio = 0.35, P= .003, lower 5% confidence limit = 0.13, upper 95% confidence limit = 0.71). Number and rate of dogs reaching treatment failure in the placebo group precluded the analysis of QoL. Pimobendan should be used as a first-line therapeutic in Doberman Pinschers for the treatment of CHF caused by DCM.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve diseaseJournal of Small Animal Practice, 2005
- Dilated cardiomyopathy: an updateVeterinary Clinics of North America: Small Animal Practice, 2004
- A Double‐Blind, Randomized, Placebo‐Controlled Study of Pimobendan in Dogs with Dilated CardiomyopathyJournal of Veterinary Internal Medicine, 2002
- Effects of Pimobendan on Adverse Cardiac Events and Physical Activities in Patients With Mild to Moderate Chronic Heart FailureCirculation Journal, 2002
- Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.Heart, 1996
- Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failureEuropean Heart Journal, 1993
- Cardiovascular Profile of UDCG 115 BS-Pimobendane and Reversibility of Catecholamine Subsensitivity in Severe Congestive Heart Failure Secondary to Idiopathic Dilated CardiomyopathyJournal of Cardiovascular Pharmacology, 1989
- Effects of Pimobendan (UD-CG 115 BS) on Left Ventricular Inotropic State in Conscious Dogs and in Patients with Heart FailureJournal of Cardiovascular Pharmacology, 1989
- Hemodynamic Profile of the Cardiotonic Agent PimobendanJournal of Cardiovascular Pharmacology, 1989